In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pair of factor XI-targeted antibodies succeeded in Phase II studies and are expected to advance into Phase III in 2025.
Regeneron Will Move Two Factor XI Agents Into Phase III
With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.
More from Strategy
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.